Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy

NCT06305143 · tracked via the Priya Life Science China tracker

Sponsor

Shanghai Eye Disease Prevention and Treatment Center

Phase

Phase 4

Started

2024-04-01

Last updated

2025-05-30

Condition(s) studied

Diabetic Macular Edema

Investigational drug(s) / intervention(s)

Conbercept

Conbercept: participants with diabetic macular edema (DME) combined with severe non-proliferative diabetes retinopathy (sNPDR) were assigned to anti-VEGF therapy over 12 months.

Study summary

The goal of this prospective multicenter open label study is to evaluate the efficacy and safety of intravitreal injection Conbercept (IVC) for the treatment of diabetic macular edema (DME) combined with severe nonproliferative diabetes retinopathy (sNPDR).

The main questions it aims to answer are:

* mean changes in best corrected visual acuity (BCVA) and central macular thickness (CMT) in comparison with baseline at 12 months after initial treatment
* proportion of eyes with visual gain ≥15 letters in Early Treatment Diabetic Retinopathy Study (ETDRS) chart and ≥2-step improvement in Diabetic Retinopathy Severity Scale (DRSS) score after 12 months of the treatment
* proportion of eyes actually underwent PRP treatment after 3 and 12 months of the treatment
* mean changes in BCVA and CMT from baseline to monthly follow-up time point
* complications and adverse effects

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * symptomatic patients aged 18 years or above with center involved diabetic macular edema in the involved eye and without clinically significant diabetic macular edema in the fellow eye defined on the basis of spectral-domain optical coherence tomography (OCT) * central macular thickness (CMT) ≥300 μm measured by OCT * the involved eyes diagnosed as severe non-proliferative diabetic retinopathy (sNPDR) confirmed by two independent experienced ophthalmologists based on the ETDRS standard seven field color fundus photographs Exclusion Criteria: * concomitant or previous macular diseases that may hinder visual improvement other than diabetic retinopathy (e.g., retinal vein occlusion, age-associated macular degeneration, uveitis, vitreomacular traction or epiretinal membrane) * history of glaucoma or optic neuropathy of any kind * previous vitreoretinal surgery or pan-retinal photocoagulation * intravitreal injection anti-VEGF drugs within 6 months or intravitreal injection glucocorticoid within 3 months * macular focal/grid laser photocoagulation within 3 months

Primary outcome measure(s)

improvement of visual acuity — from baseline to 12 months after initial intravitreal Conbercept injection
mean change in best corrected visual acuity letter score

Trial sites (1)

Facility	City	Region	Status
Shanghai Eye Diseases Prevention &Treatment Center	Shanghai	Shanghai Municipality

More Shanghai Eye Disease Prevention and Treatment Center trials in China

Shanghai Children and Adolescent Diabetes Eye Study Recruiting

Shanghai Child and Adolescent Large-scale Eye Study -High Myopia Registration Enrolling by invitation

Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses Enrolling by invitation

Efficacy of Multi-Type Photolithography Flat Microstructure Lenses for Childhood Myopia Control Starting soon

Light Diffraction Glasses in Preventing and Controlling Myopia in Adolescents Active, not recruiting

Other trials for the same condition

Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema Active, not recruiting

Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage Starting soon

Gene Therapy for Diabetic Macular Edema Recruiting

A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China Active, not recruiting

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06305143 on ClinicalTrials.gov ↗ ← All trials in China